Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of PBI-4050 in Healthy Subjects

Next Previous
Search
Trial Profile

A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of PBI-4050 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fezagepras (Primary)
  • Indications Alstrom's Syndrome; Cystic fibrosis; Diabetic nephropathies; Hypertriglyceridaemia; Idiopathic pulmonary fibrosis; Liver disorders; Metabolic syndrome; Non-alcoholic fatty liver disease; Scleroderma; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Liminal BioSciences

    • Most Recent Events

    • 14 Mar 2022 Results published in the Liminal BioSciences Media Release
    • 18 Nov 2021 Status changed from recruiting to completed.
    • 15 Nov 2021 According to a Liminal BioSciences media release, the company has completed the clinical phase of the study and is in the process of evaluating the complete pharmacokinetic (PK) data set from the MAD portion expects to complete this analysis before the end of the fourth quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top